Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FCR001
- Development stage
- Phase 2
- Lead developer
- Tourmaline Bio
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
**FCR001** is an investigational, cryopreserved donor-derived facilitated allogeneic hematopoietic stem-cell therapy developed to establish durable mixed donor-recipient hematopoietic chimerism and donor-specific immune tolerance. The product is manufactured from mobilized peripheral blood obtained from the living organ donor and contains CD34-positive hematopoietic stem and progenitor cells, facilitating cells, and a controlled dose of alpha-beta T cells. It is administered after nonmyeloablative conditioning in conjunction with living-donor kidney transplantation, with the therapeutic objective of eliminating chronic maintenance immunosuppression while preserving graft function. Talaris Therapeutics discontinued its FREEDOM-1 and FREEDOM-2 kidney-transplant trials in February 2023 because of slow enrollment; ImmunoFree subsequently acquired rights to FCR001 and the transplant-tolerance business. ([tts2022.org](https://tts2022.org/images/sponsor_logos/Talaris/TAL2112663A_1-pager_Overall_Clinical_Trial_Program_updated_21July2022.pdf))
- Other names
- Talaris cell therapyFacilitating Cell-based Therapy
Beyond the preview
Go deeper on FCR001.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FCR001.